Brady Collins
The hepatitis B vaccine is a medication used to prevent hepatitis B infection, which can lead to chronic liver failure and hepatocellular carcinoma. The first hepatitis B vaccine was approved for use in the United States in 1981, with a recombinant version coming to market in 1986. The development of the vaccine was a significant milestone in the history of medicine, as it was the first anti-cancer vaccine, offering protection against liver cancer caused by hepatitis B. Today, the vaccine is widely recommended and has led to a significant decline in hepatitis B infections and related complications worldwide.
| Characteristics | Values |
|---|---|
| Date first approved | 1981 |
| Date recombinant version approved | 1986 |
| Date monovalent vaccines replaced by combined vaccines in Italy | 1999 |
| Date PreHevbri approved for medical use in the European Union | April 2022 |
| Countries with hepatitis B vaccination in their national childhood immunization programs | 190 |
| Number of doses | 3 or 4 |
| Time period over which doses are administered | 6 months |
| Percentage of people protected in routine immunization | >95% |
| Number of chronic carriers of hepatitis B virus (HBV) globally | 296 million |
| Number of deaths per year due to complications from HBV | 820,000 |
Explore related products
What You'll Learn
The first hepatitis B vaccine was approved in 1981
The first hepatitis B vaccine was approved in the United States in 1981. This first vaccine was a plasma-derived vaccine, also known as an "inactivated" vaccine. It was manufactured by Merck Pharmaceuticals and sold under the name "Heptavax". This vaccine was created using blood from hepatitis B virus-infected donors, which was then subjected to multiple steps to inactivate the viral particles.
The development of the hepatitis B vaccine was a significant advancement in the prevention of hepatitis B infection, which can lead to chronic liver failure, hepatocellular carcinoma, and liver cancer. Worldwide, chronic hepatitis B and C are responsible for 80% of all liver cancer cases. Therefore, the hepatitis B vaccine is often referred to as the first anti-cancer vaccine.
In 1986, a second-generation, genetically engineered (or DNA recombinant) hepatitis B vaccine was introduced to the market. This newer version of the vaccine uses only a small part of the virus and is, therefore, safer and unable to cause infection. It is more than 90% effective when the full vaccine series is completed.
Since the introduction of the hepatitis B vaccine, significant progress has been made in reducing new cases of hepatitis B infection. Vaccination is now recommended for nearly all babies at birth in the United States, and many countries have implemented routine infant vaccination programs. This has resulted in a marked reduction in liver cancer rates, especially in countries with high rates of hepatitis B infection.
The hepatitis B vaccine is typically given in three or four doses over a six-month period and provides long-term protection. It is generally safe, with serious side effects being very uncommon.
Hepatitis B Vaccine: Effective Defense Against Hepatitis C?
You may want to see also
Explore related products
Vaccination of newborns has reduced the risk of infection
The first hepatitis B vaccine was approved in the United States in 1981. A recombinant version came to market in 1986. The hepatitis B vaccine is the first anti-cancer vaccine because it can help prevent liver cancer. Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Chronic infection over the course of a lifetime can lead to liver damage, liver failure, liver cancer, or even death.
In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection but has also led to a marked reduction in liver cancer. For example, in Taiwan, the implementation of a nationwide hepatitis B vaccination program in 1984 was associated with a decline in the incidence of childhood hepatocellular carcinoma. Similarly, since universal childhood vaccination was recommended in 2006, hepatitis A cases in the US dropped by 95%.
The hepatitis B vaccine has been tested extensively for safety and efficacy, and when administered within 24 hours of birth, it is highly effective in preventing newborn infection. According to the CDC, from 2011 to 2019, rates of reported cases of acute hepatitis B remained low among children and adolescents aged 0-19 years and among people aged 20-29 years, likely due to the implementation of childhood hepatitis B vaccine recommendations published by the CDC in 1991.
The BCG Vaccine: Why Does It Leave a Mark?
You may want to see also
Explore related products
Hepatitis B is the first anti-cancer vaccine
Hepatitis B is a virus that was discovered in 1965 by Dr. Baruch Blumberg, who won the Nobel Prize for his discovery. The virus was originally called the "Australia Antigen" as it was named after an Australian Aborigine whose blood sample reacted with an antibody in an American hemophilia patient's serum. Hepatitis B can become chronic and lead to serious health problems like liver damage or cancer. It is passed from mother to baby during childbirth, through unprotected sex, by sharing personal items like razors or toothbrushes, through direct contact with open wounds, or by sharing.
The hepatitis B vaccine is a medication used to prevent hepatitis B infection, which can lead to chronic liver failure and hepatocellular carcinoma. The first dose is recommended within 24 hours of birth, with either two or three more doses given after that. The hepatitis B vaccine is the first anti-cancer vaccine because it can help prevent liver cancer. Worldwide, chronic hepatitis B and hepatitis C cause 80% of all liver cancers, which is the second most common cause of cancer-related deaths. Therefore, a vaccine that protects against hepatitis B infection can also help prevent liver cancer.
The first hepatitis B vaccine was approved in the United States in 1981, with a recombinant version coming to market in 1986 that replaced the original blood-derived vaccine. In 1991, the United States began a strategy to achieve universal vaccination of infants beginning at birth for hepatitis B. Vaccination is the most effective way to control and prevent acute and chronic hepatitis B, including cirrhosis and HCC, on a global scale. According to WHO recommendations, 190 countries worldwide have introduced hepatitis B vaccination into their national childhood immunization programs, with excellent safety, immunogenicity, and effectiveness profiles.
The implementation of a nationwide hepatitis B vaccination program in Taiwan in 1984 was associated with a decline in the incidence of childhood hepatocellular carcinoma. In the UK, the vaccine is offered to men who have sex with men (MSM), usually as part of a sexual health check-up. Vaccination against hepatitis B is also required for all healthcare and laboratory staff in many areas.
How Aminoglycosides Enhance Vaccine Efficacy
You may want to see also
Explore related products
Vaccination is recommended for healthcare workers
The first hepatitis B vaccine was approved in the United States in 1981. A recombinant version came to market in 1986. It is recommended for nearly all babies at birth in the US, and many countries routinely vaccinate infants against hepatitis B.
Healthcare workers are recommended to get the hepatitis B vaccine due to their constant exposure to patients and other healthcare workers. Hepatitis B is a contagious liver infection caused by the hepatitis B virus (HBV). It can range from a mild illness lasting a few weeks to a serious long-term illness that can lead to liver damage or, in some cases, liver cancer. The hepatitis B virus is transmitted through blood or other bodily fluids, and healthcare workers are at risk of exposure to these on a daily basis.
The vaccine is safe and effective, and it is recommended that healthcare workers receive the full series of doses for the best protection. The hepatitis B vaccine is given in three or four doses over a six-month period, and it provides long-term protection. It is available by itself or in combination with other vaccines.
In many areas, vaccination against hepatitis B is required for all healthcare and laboratory staff. This includes countries with high rates of hepatitis B infection, where vaccination of newborns has also significantly reduced the risk of infection and lowered the incidence of liver cancer.
The hepatitis B vaccine is also recommended for other adults who are at risk of exposure to the virus, such as those with diabetes mellitus, men who have sex with men, and those who share personal items like razors or toothbrushes.
TB Vaccine: Available in the US?
You may want to see also
Explore related products
The hepatitis B virus was discovered in 1965
In the 1960s, researchers discovered the hepatitis B surface antigen, and the virus was fully identified in 1970. By the 1940s, hepatitis A and B were recognised as separate diseases. However, it wasn't until 1981 that the first hepatitis B vaccine was approved for use in the United States. This "inactivated" type of vaccine was manufactured by Merck Pharmaceuticals as "Heptavax" and was the first commercial hepatitis B virus vaccine. The use of this vaccine was discontinued in 1990. In 1986, a second-generation genetically engineered (or DNA recombinant) hepatitis B vaccine was developed, replacing the original blood-derived vaccine.
Hepatitis B is a potentially serious condition that can lead to chronic liver failure and hepatocellular carcinoma. The hepatitis B vaccine is a medication used to prevent hepatitis B infection. Vaccination is the most effective way to control and prevent acute and chronic hepatitis B on a global scale. The World Health Organization (WHO) recommends a pentavalent vaccine, combining vaccines against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B with the vaccine against hepatitis B.
The hepatitis B vaccine is usually given in three or four doses over six months, providing long-term protection. The first dose is recommended within 24 hours of birth, with two or three more doses given after that. This includes those with poor immune function, such as those with HIV/AIDS or those born prematurely. In healthy people, routine immunisation results in more than 95% of people being protected.
Immunization vs Vaccination: What's the Difference?
You may want to see also
Frequently asked questions
The first hepatitis B vaccine was approved for use in the United States in 1981.
The first commercial hepatitis B vaccine was called Heptavax.
Heptavax was a "inactivated" type of vaccine made from plasma.
A recombinant version of the vaccine came to market in 1986.
